Pivotal Alzheimer’s Trial Begins Final Patient Treatment
Actinogen has fully randomized 247 patients to its Phase 2b/3 XanaMIA study in mild to moderate Alzheimer’s disease, and...
Jon Napitupulu
Ovid Reports Phase 1 Data for Unique KCC2 Activator OV350
In a randomized, placebo-controlled Phase 1 study of 16 healthy volunteers, intravenous OV350 met its primary safety, tolerability, and...
Pioneering Pancreatic Cancer Trial Randomizes First Patient
Revolution Medicines has randomized the first patient in RASolute 304, a global, open-label Phase 3 study testing daraxonrasib as...
Orelabrutinib Phase 2b Lupus Study Meets Primary Endpoint
In a 187-patient Phase 2b study in systemic lupus erythematosus, orelabrutinib 75 mg once daily achieved a 57.1% SRI-4...
Silexion Submits Pancreatic Cancer Trial App in Israel
Preclinical data for SIL204 reported up to 99.7% cancer cell inhibition across multiple KRAS mutations, and recently completed two-species...
Beacon’s XLRP Gene Therapy Trial Treats Its First Patient
Interim Phase 2 data for laru-zova have shown sustained gains on low-luminance visual acuity and microperimetry, with participants generally...
Arch Biopartners’ Phase II AKI Trial Gets Ethics Approval
Arch Biopartners’ Phase II study in cardiac surgery–associated acute kidney injury (CS-AKI) targets enrollment of 240 on-pump patients, randomizing...
Evolveimmune Initiates Phase 1 Dosing for Solid Tumors
No efficacy or safety data were disclosed. EvolveImmune has dosed the first subject in EIU-104101 (NCT07217171), a first-in-human Phase...
MRT-2359 Shows Compelling Activity in Prostate Cancer Trial
In an interim Phase 1/2 readout in metastatic castration‑resistant prostate cancer (mCRPC), the combination of Monte Rosa’s GSPT1 degrader...
New Hope in Phase 3 Trial for Pancreatic Cancer
Immuneering completed End-of-Phase 2 interactions with the FDA and received EMA scientific advice supporting a global Phase 3 registrational...